Item 2.02 Results of Operations and Financial Condition.

Kintara Therapeutics, Inc. (the "Company") issued a press release on September 29, 2021, disclosing financial information and operating metrics for the year ended June 30, 2021, and providing a corporate update. A copy of the Company's press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 7.01 Regulation FD Disclosure.

See "Item 2.02 Results of Operation and Financial Condition" above.

The information in this Current Report on Form 8-K under Items 2.02 and 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by a specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits.




Exhibit No.       Description

99.1                Press release of Kintara Therapeutics, Inc. issued September
                  29, 2021
104               Cover Page Interactive Data File (embedded within the Inline XBRL
                  document)




--------------------------------------------------------------------------------

[[Image Removed]]

© Edgar Online, source Glimpses